Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib with Reduced-Intensity Allo-SCT for Lymphoid Malignancies
NCT00439556Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2007
- Primary completion
- Jun 2018
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in lymphoid malignancy, sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2007; status: completed.
02
Drugs
bortezomib
03
Conditions
lymphoid malignancy
Beyond the preview
Go deeper on NCT00439556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00439556.